☆ 4.3 Article

Timing of convalescent plasma administration and 28-day mortality in COVID-19 pneumonia

JOURNAL OF INVESTIGATIVE MEDICINE (2022)

Related references

Note: Only part of the references are listed.

Article Pathology

Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG

Eric Salazar et al.

Summary: Convalescent plasma therapy containing high-titer anti-spike protein RBD IgG has shown to significantly reduce mortality in hospitalized COVID-19 patients when transfused within 44 hours, confirming previous findings and showing promise in the treatment of the disease.

AMERICAN JOURNAL OF PATHOLOGY (2021)

Add to Collection

Article Hematology

Early mortality benefit with COVID-19 convalescent plasma: a matched control study

Aarthi G. Shenoy et al.

Summary: The study demonstrated that patients with COVID-19 who received CCP had a decreased risk of death at 7 and 14 days, but not 28 days after transfusion, compared to matched controls.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

D. M. Weinreich et al.

Summary: Recent data indicate that complications and death from Covid-19 may be related to high viral loads. In this trial involving nonhospitalized patients, a cocktail of two neutralizing monoclonal antibodies (REGN-COV2) reduced viral load, with a greater effect in patients with no immune response or high viral load at baseline. Safety outcomes were similar between REGN-COV2 dose groups and the placebo group.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

R. Libster et al.

Summary: A randomized, double-blind, placebo-controlled trial of convalescent plasma with high IgG titers against SARS-CoV-2 in older adult patients within 72 hours after the onset of mild Covid-19 symptoms found that early administration of high-titer convalescent plasma reduced the progression of Covid-19 in mildly ill infected older adults.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19

M. J. Joyner et al.

Summary: This study found that higher anti-SARS-CoV-2 IgG antibody levels in convalescent plasma were associated with a lower risk of death among patients hospitalized with Covid-19 who were not receiving mechanical ventilation. The association between antibody levels and mortality risk was moderated by mechanical ventilation status, with no significant effect seen in patients who had already received ventilation.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

V. A. Simonovich et al.

Summary: There were no significant differences observed in clinical status or overall mortality between patients treated with convalescent plasma and those who received placebo in the treatment of severe Covid-19 pneumonia. The study results indicate that both groups had similar clinical outcomes and mortality rates after 30 days.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Peter Chen et al.

Summary: LY-CoV555, a neutralizing antibody, showed promising results in reducing viral load, improving symptoms, and lowering the risk of hospitalization among patients with mild or moderate Covid-19. While one of the doses appeared to accelerate the decline in viral load, others did not show significant effects by day 11.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19 A Randomized Clinical Trial

Lise J. Estcourt et al.

Summary: Among critically ill adults with confirmed COVID-19, treatment with 2 units of high-titer, ABO-compatible convalescent plasma had a low likelihood of providing improvement in the number of organ support-free days.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Review Medicine, General & Internal

The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis

Stephen A. Klassen et al.

Summary: Studies show that COVID-19 convalescent plasma can lower mortality rates in patients, especially when administered early and with higher antibody titers.

MAYO CLINIC PROCEEDINGS (2021)

Add to Collection

Article Medicine, General & Internal

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Peter W. Horby et al.

Summary: Convalescent plasma therapy did not improve survival or other clinical outcomes in hospitalized COVID-19 patients.

LANCET (2021)

Add to Collection

Article Multidisciplinary Sciences

Risk factors for COVID-19 mortality: The effect of convalescent plasma administration

Martin R. Salazar et al.

Summary: The administration of convalescent plasma in COVID-19 pneumonia patients admitted to the hospital may be associated with improved outcomes, with lower 28-day mortality rates observed in those who received the treatment compared to those who did not.

PLOS ONE (2021)

Add to Collection

Article Infectious Diseases

Is convalescent plasma futile in COVID-19? A Bayesian re-analysis of the RECOVERY randomized controlled trial

F. W. Hamilton et al.

Summary: This study highlights the potential benefit of convalescent plasma in reducing mortality among COVID-19 patients, with varying effectiveness based on antibody status and timing of presentation. Patients who present within 7 days without detectable antibodies may experience a significant mortality reduction, while those already with antibodies may not derive as much benefit from convalescent plasma therapy. Bayeisan analysis provides valuable insights into treatment efficacy compared to traditional frequentist methods.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Article Multidisciplinary Sciences

Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19

Neima Briggs et al.

Summary: The study found that early administration of CCP can improve outcomes in patients with moderate-to-severe COVID-19, while improvement was not observed with late administration of CCP. Timing of administration should be considered in future trials.

PLOS ONE (2021)

Add to Collection

Article Multidisciplinary Sciences

Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection

Arvind Gharbharan et al.

Summary: A clinical trial on 86 COVID-19 patients treated with convalescent plasma showed no overall clinical benefit, as most patients already had potent antibodies upon admission, leading to the trial being terminated prematurely.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Medicine, Research & Experimental

A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia

Katharine J. Bar et al.

Summary: This study assessed the efficacy of CCP in severely ill, hospitalized adults with COVID-19 pneumonia, showing significant benefits in clinical severity score and 28-day mortality. The results suggest that CCP may benefit select populations, especially those with comorbidities who are treated early.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Article Medicine, Research & Experimental

Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19

Shanna A. Arnold Egloff et al.

Summary: The study showed that convalescent plasma (CP) is significantly associated with decreased risk of in-hospital mortality in patients with COVID-19, highlighting the importance of real-world evidence and the need for further evaluation before dismissing CP as a viable therapy.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Article Medicine, Research & Experimental

A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia

Cristina Avendano-Sola et al.

Summary: The study conducted in Spain involving 27 hospitals showed that convalescent plasma (CP) can significantly reduce the risk of progression to invasive mechanical ventilation or ECMO treatment, or death within 28 days for COVID-19 patients. However, the difference was not significant at 14 days and there was no significant improvement in overall survival.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Review Medicine, General & Internal

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review

Vanessa Piechotta et al.

Summary: Convalescent plasma and hyperimmune immunoglobulin are being investigated as potential therapies for COVID-19, with a living systematic review approach being used to assess their effectiveness and safety. The current evidence suggests that convalescent plasma does not reduce all-cause mortality or significantly improve clinical outcomes for individuals with moderate to severe disease, but its impact on other outcomes remains uncertain. Further ongoing studies are needed to determine the full potential of these interventions.

COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2021)

Add to Collection

Article Medicine, Research & Experimental

A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19

Max R. O'Donnell et al.

Summary: This study found that the use of convalescent plasma was not associated with significant improvement in the clinical status at day 28 for severe COVID-19 patients, but it was related to significantly improved survival rates.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Article Medicine, General & Internal

RBD-specific polyclonal F(ab′)2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial

Gustavo Lopardo et al.

Summary: Although the trial did not reach the primary endpoint, there was clinical improvement observed in hospitalized patients with SARS-CoV-2 pneumonia, especially in those with severe disease.

ECLINICALMEDICINE (2021)

Add to Collection

Article Pathology

Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality

Eric Salazar et al.

AMERICAN JOURNAL OF PATHOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19 A Randomized Clinical Trial

Ling Li et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Multidisciplinary Sciences

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Davide F. Robbiani et al.

NATURE (2020)

Add to Collection

Article Medicine, General & Internal

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)

Anup Agarwal et al.

BMJ-BRITISH MEDICAL JOURNAL (2020)

Add to Collection

Review Medicine, General & Internal

Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis

Min Seo Kim et al.

PLOS MEDICINE (2020)

Add to Collection

© Peeref 2019-2024. All rights reserved.